Martin Haase will leave Bruker BioSciences at the end of April to “pursue other interests,” the com-pany said this week. Haase is currently senior vice president of Bruker BioSciences, based in Billerica, Mass., as well as president and CEO of its subsidiary Bruker AXS. He will continue to serve on the board of directors of Bruker BioSciences until December.
David Lawrence has become an advisor to the board of directors of SomaLogic. Until 2002, he was CEO and chairman of the board of Kaiser Foundation Health Plan and Kaiser Foundation Hospitals. He joined Kaiser Permanente in 1981. Prior to that, he was health officer and director of human services in Multnomah County, Oregon, and director of Medex at the University of Washington. Lawrence holds a BA from Amherst College, a medical degree from the University of Kentucky, and a master of public health degree from the University of Washington. SomaLogic, based in Boulder, Colo., is developing applications for its aptamer technology (see story, p. 1).
Michael Kranda has joined the board of directors of PTC Therapeutics. Kranda, director of biotechnology venture investments of Vulcan Capital, used to be CEO of Oxford GlycoSciences. He also was president and COO of Immunex, and former chief of staff to King County prosecutor Norm Maleng. He holds an MBA from the University of Washington. PTC Therapeutics, based in South Plainfield, NJ, applies RNA biology to modulate gene expression in order to develop small molecule drugs.
J. Donald Payne has been ap- pointed to the board of directors of Boston Biomedica, located in West Bridgewater, Mass., succeeding William Wilson, who left the board last year. Payne will also serve as chairman on the board’s audit committee. Since 2001, he has been president and director of Nanospectra Biosciences.
Payne holds an undergraduate degree in business administration from Texas A&M University and an MBA from Rice University. BBI, among other activities, provides products and services to the diagnostics and life sciences industry in order to improve the preparation of specimens for genomic and proteomic testing.